Laser remains standard of DME therapy

Article

Combination therapy also showing promise

The International Diabetes Federation estimates that in the European countries of Austria, France, Germany, Italy, Portugal and Spain there are 22.1 million people currently living with diabetes, and the Center for Disease Control and Prevention estimates that 25.8 million Americans also have the disease. As the global population continues to age, there is increasing pressure for treatments that are both clinically effective and economically efficient. Advances in laser treatment protocols allow it to meet both of these criteria, and combined therapies are showing promise as well.

The evolution of laser photocoagulation

The packet of photons in each micropulse contains much less energy than a whole pulse. When the train of micropulses reaches the target tissue, thermal elevation and its diffusion from the impact zone are limited significantly. The result is that the sublethal treatment affects only a small collection of retinal epithelial cells and just the tips of the photoreceptors, as opposed to the large crater created with standard continuous-wave laser therapies. In essence, the visible burn has been eliminated.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
Related Content
© 2025 MJH Life Sciences

All rights reserved.